Multiple Myeloma
Conditions
Brief summary
To describe patterns of adherence and pilot baseline measures to investigate factors associated with lower adherence to lenalidomide in older adults with myeloma.
Interventions
OTHERMedication Event Monitoring System
-Microchipped bottle cap
Sponsors
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥65 * Receiving lenalidomide for treatment of multiple myeloma. * Anticipated to receive ongoing care at Siteman Cancer Center and its satellite sites * Able to read and understand English. * Able to understand and willing to sign an IRB-approved written informed consent document.
Exclusion criteria
* Estimated life expectancy \<6 months. * Anticipated duration of lenalidomide therapy \<3 months. * Residing in a nursing facility where their medications are administered to them OR patient reports they do not self-administer their own medications.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adherence rate as measured by the number of days in which the lenalidomide pill bottle was open | Through completion of study (estimated to be 3 months) | -Participants will be given a pill diary in which they will record if they opened the pill bottle without taking a medication (e.g. to ascertain remaining supply) to adjust the adherence rate accordingly |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adherence rate as measured by a modified Brief Adherence Rating Scale | Through completion of study (estimated to be 3 months) | * Participants will fill out a brief survey about taking lenalidomide and an estimate of their adherence using a visual analog scale * Scored 0-100%, 0% = lenalidomide not taken on any days and 100% = lenalidomide taken every day |
Countries
United States
Outcome results
None listed